JW LIFESCIENCE CORPORATION
Financials
Valuation Metrics
JW LIFESCIENCE CORPORATION's Market Cap is ₩1769B. At end of 2025 it was ₩2035B. Ranked #892 of 2,436 in KR market (top 37%), #474 of 787 on KOSPI (top 60%), #97 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 41%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 176.87B KRW | KR#892/2,436 Sec#97/234 |
| Revenue | 252.72B KRW | KR#895/2,436 Sec#45/234 |
| Net Income | 29.19B KRW | KR#519/2,436 Sec#37/234 |
| Total Assets | 313.55B KRW | KR#997/2,436 Sec#67/234 |
| Net Assets | 218.75B KRW | KR#879/2,436 Sec#60/234 |
| Employees | 328 | KR#733/2,436 Sec#64/234 |
| Value | ||
| P/E | 6.06x | KR#383/2,436 Sec#17/234 |
| P/B | 0.81x | KR#1,296/2,436 Sec#78/234 |
| PEG | 0.64x | KR#701/2,436 Sec#43/234 |
| P/S | 0.70x | KR#1,151/2,436 Sec#57/234 |
| EV/EBITDA | 6.24x | KR#317/2,436 Sec#10/234 |
| FCF Yield | 15.82% | KR#428/2,436 Sec#9/234 |
| Profitability | ||
| ROE | 13.34% | KR#314/2,436 Sec#18/234 |
| ROA | 9.31% | KR#237/2,436 Sec#20/234 |
| Op. Margin | 13.20% | KR#340/2,436 Sec#32/234 |
| Revenue Growth | -7.44% | KR#1,788/2,436 Sec#166/234 |
| Earnings Growth | 9.49% | KR#839/2,436 Sec#56/234 |
| Financial Health | ||
| Debt Ratio | 43.34% | KR#158/2,436 Sec#21/234 |
| Total Debt | 40.34B KRW | KR#1,068/2,436 Sec#75/234 |
| FCF | 27.98B KRW | KR#430/2,436 Sec#23/234 |
| Cash | 8.86B KRW | KR#1,739/2,436 Sec#143/234 |
| Current Ratio | 1.09x | KR#1,722/2,436 Sec#175/234 |
| Net Debt/EBITDA | 0.94x | KR#790/2,436 Sec#53/234 |
| Dividend | ||
| Div. Yield | 4.92% | KR#284/2,436 Sec#10/234 |
| Div. Growth | 10.00% | KR#583/2,436 Sec#32/234 |
| Performance | ||
| 1Y Return | -8.67% | KR#920/2,436 Sec#68/234 |
| 1M Return | -2.70% | KR#1,182/2,436 Sec#114/234 |
| From 52W High | -28.31% | KR#356/2,436 Sec#21/234 |
| 1Y MDD | -30.84% | KR#229/2,436 Sec#14/234 |
| Trading | ||
| Volume | 42,659 shares | KR#1,442/2,436 Sec#143/234 |
| Foreign Own. | 14.47% | KR#330/2,436 Sec#24/234 |
| Per Share | ||
| EPS | 1,843 KRW | KR#421/2,436 Sec#27/234 |
| BPS | 14,127 KRW | KR#692/2,436 Sec#47/234 |
Company Info
Established in 1994, this company produces and sells professional pharmaceutical infusions, including 3-Chamber nutritional infusions, which are manufactured by only a few companies. It has signed licensing-out and export contracts with global infusion manufacturer Baxter Corporation, becoming the first in Asia to obtain EU-GMP certification for its TPN production facility, recognizing its world-class production infrastructure. The HP Research Center is pursuing global growth through the development of non-PVC materials and the launch of TPN products, leveraging infusion-related technologies. JW Life Science is headquartered in Dangjin, Chungcheongnam-do.